Loading clinical trials...
Loading clinical trials...
A Phase 3 Trial of Fianlimab (Anti-LAG-3) and Cemiplimab Versus Pembrolizumab in the Adjuvant Setting in Patients With Completely Resected High-risk Melanoma
Conditions
Interventions
Fianlimab
Cemiplimab
+2 more
Locations
211
United States
UC San Diego
La Jolla, California, United States
UCSF Medical Center at Mission Bay
San Francisco, California, United States
John Wayne Cancer Institute (JWCI)
Santa Monica, California, United States
The Melanoma And Skin Cancer Institute
Englewood, Colorado, United States
Miami Cancer Institute at Baptist Health, Inc.
Miami, Florida, United States
Orlando Health
Orlando, Florida, United States
Start Date
January 16, 2023
Primary Completion Date
May 16, 2028
Completion Date
February 15, 2030
Last Updated
May 13, 2025
NCT07177937
NCT02621021
NCT03050268
NCT05969860
NCT03340506
NCT04693377
Lead Sponsor
Regeneron Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions